FLT3 and acute myeloid leukemia: Quizartinib is an oral, highly potent and selective type II FLT3 inhibitor5, 6 that is currently being investigated in a phase 3 study in patients with newly diagnosed FLT3‐ITD–mutated AML (QuANTUM‐First: NCT02668653).